Ultrasonographic assessment of bone erosions in the different subtypes of systemic lupus erythematosus arthritis: comparison with computed tomography

Piga, Matteo; Saba, Luca; Gabba, Alessandra; Congia, Mattia; Balestrieri, Antonella; Mathieu, Alessandro; Cauli, Alberto

doi:10.1186/s13075-016-1125-8

Cited by 36 publications

(32 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Novel insights suggest that erosive damage, as assessed by musculoskeletal ultrasonography (US), occurs in up to 47% of patients with SLE [ 1 , 4 – 8 ]. It is likely that such an erosive phenotype of SLE arthritis may underlie specific pathogenic mechanisms [ 1 ].…”

Section: Introductionmentioning

confidence: 99%

Anti-carbamylated protein antibodies as a new biomarker of erosive joint damage in systemic lupus erythematosus

et al. 2018

View full text Add to dashboard Cite

BackgroundThe application of more sensitive imaging techniques, such as ultrasonography (US), changed the concept of non-erosive arthritis in systemic lupus erythematosus (SLE), underlining the need for biomarkers to identify patients developing the erosive phenotype. Anti-citrullinated peptide antibodies (ACPA), associated with erosions in inflammatory arthritis, have been identified in about 50% of patients with SLE with erosive arthritis. More recently, anti-carbamylated proteins antibodies (anti-CarP) have been associated with erosive damage in rheumatoid arthritis. We aimed to assess the association between anti-CarP and erosive damage in a large SLE cohort with joint involvement.MethodsWe evaluated 152 patients (male/female patients 11/141; median age 46 years, IQR 16; median disease duration 108 months, IQR 168). All patients underwent blood draw to detect rheumatoid factor (RF) and ACPA (commercial enzyme-linked immunosorbent assay (ELISA) kit), and anti-CarP (“home-made” ELISA, cutoff 340 aU/mL). The bone surfaces of the metacarpophalangeal and proximal interphalangeal joints were assessed by US: the presence of erosions was registered as a dichotomous value (0/1), obtaining a total score (0–20).ResultsThe prevalence of anti-CarP was 28.3%, similar to RF (27.6%) and significantly higher than ACPA (11.2%, p = 0.003). Erosive arthritis was identified in 25.6% of patients: this phenotype was significantly associated with anti-CarP (p = 0.004). Significant correlation between anti-CarP titer and US erosive score was observed (r = 0.2, p = 0.01).ConclusionsSignificant association was identified between anti-CarP and erosive damage in SLE-related arthritis, in terms of frequency and severity, suggesting that these antibodies can represent a biomarker of severity in patients with SLE with joint involvement.

show abstract

Section: Introductionmentioning

confidence: 99%

Anti-carbamylated protein antibodies as a new biomarker of erosive joint damage in systemic lupus erythematosus

et al. 2018

View full text Add to dashboard Cite

show abstract

“…7), 31 and MRI, US, and computed tomography can help in this diagnosis. 32 This form of SLE is relatively rare and seen in only 2% of the patients. 2.…”

Section: Imaging Featuresmentioning

confidence: 99%

Musculoskeletal Manifestations of Non-RA Connective Tissue Diseases: Scleroderma, Systemic Lupus Erythematosus, Still's Disease, Dermatomyositis/Polymyositis, Sjögren's Syndrome, and Mixed Connective Tissue Disease

Jacques

Sudoł‐Szopińska

Larkman

et al. 2018

Semin Musculoskelet Radiol

View full text Add to dashboard Cite

The most common systemic rheumatologic conditions are connective tissue diseases (including rheumatoid arthritis [RA]) followed by spondyloarthropathy. With the advent of biotherapies and imaging biomarkers, development in the imaging of RA and spondyloarthropathies has received substantial attention in the literature. This article details the various musculoskeletal imaging features of the other connective tissue diseases such as scleroderma and progressive systemic sclerosis, systemic lupus erythematosus, Still's disease, dermatomyositis and polymyositis, Sjögren's syndrome, and mixed connective tissue disease.

show abstract

“…Therefore, MSUS can be used in juvenile SLE as a first method for evaluation of synovitis, tenosynovitis and even bone erosions. Recent US studies report bone erosions in SLE adult patients and not only in the rhupus subtype [54,55].…”

Section: Juvenile Systemic Lupus Erythematosusmentioning

confidence: 99%

What’s new in musculoskeletal ultrasound in pediatric rheumatology?

Spârchez

Fodor

2018

Med Ultrason

View full text Add to dashboard Cite

Musculoskeletal ultrasound (MSUS) has become almost indispensable in the rheumatology settings nowadays, allowing early diagnosis, careful guidance during procedures such as joint injections and therapy monitoring. Nonetheless, the applicability of MSUS in pediatric population is still limited. Recently, a standardized MSUS examination procedure in pediatric patients with rheumatic diseases, definitions for synovitis and the sonographic features of joints in healthy children has been developed. Also, important data on age-related vascularization and ossification of joints in children have been published. Much work still needs to be done in the field. As juvenile idiopathic arthritis seems to be the most common use of MSUS in pediatric rheumatology, specific definitions and assessment techniques for enthesitis, tenosynovitis, bone and cartilage damage in children are very much expected. In this article, we will review briefly the current evidence-based knowledge regarding MSUS potential applications in the pediatric rheumatology clinical practice, along with an overview of the recent information about US appearance of musculoskeletal structures in healthy children.

show abstract

Ultrasonographic assessment of bone erosions in the different subtypes of systemic lupus erythematosus arthritis: comparison with computed tomography

Cited by 36 publications

References 28 publications

Anti-carbamylated protein antibodies as a new biomarker of erosive joint damage in systemic lupus erythematosus

Anti-carbamylated protein antibodies as a new biomarker of erosive joint damage in systemic lupus erythematosus

Musculoskeletal Manifestations of Non-RA Connective Tissue Diseases: Scleroderma, Systemic Lupus Erythematosus, Still's Disease, Dermatomyositis/Polymyositis, Sjögren's Syndrome, and Mixed Connective Tissue Disease

What’s new in musculoskeletal ultrasound in pediatric rheumatology?

Contact Info

Product

Resources

About